These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 20668478)

  • 1. Targeted therapies: Biomarkers in NSCLC for selecting cetuximab therapy.
    Stinchcombe TE; Socinski MA
    Nat Rev Clin Oncol; 2010 Aug; 7(8):426-8. PubMed ID: 20668478
    [No Abstract]   [Full Text] [Related]  

  • 2. Ramucirumab combination improves OS and PFS in NSCLC.
    Izzo C
    Am J Manag Care; 2014 Mar; 20(5 Spec No.):E9. PubMed ID: 25618624
    [No Abstract]   [Full Text] [Related]  

  • 3. Cetuximab in non-small cell lung cancer.
    Ademuyiwa FO; Hanna N
    Expert Opin Biol Ther; 2008 Jan; 8(1):107-13. PubMed ID: 18081540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Promising targeted molecular therapies for the future years in non-small-cell lung cancer].
    Soria JC
    Rev Pneumol Clin; 2006 Feb; 62 Spec no 1():1S35-6. PubMed ID: 16719155
    [No Abstract]   [Full Text] [Related]  

  • 5. A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer.
    Kim ES; Mauer AM; William WN; Tran HT; Liu D; Lee JJ; Windt P; Hong WK; Vokes EE; Herbst RS
    Cancer; 2009 Apr; 115(8):1713-22. PubMed ID: 19208430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted therapies: Cetuximab plus chemotherapy in patients with advanced NSCLC.
    Rasul KI; Kerr DJ
    Nat Rev Clin Oncol; 2009 Sep; 6(9):499-500. PubMed ID: 19707238
    [No Abstract]   [Full Text] [Related]  

  • 7. Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors.
    Morelli MP; Cascone T; Troiani T; De Vita F; Orditura M; Laus G; Eckhardt SG; Pepe S; Tortora G; Ciardiello F
    Ann Oncol; 2005 May; 16 Suppl 4():iv61-68. PubMed ID: 15923432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab extends survival for patients with nonsquamous non-small-cell lung cancer.
    Belani CP; Ramalingam S
    Clin Lung Cancer; 2005 Mar; 6(5):267-8. PubMed ID: 15845175
    [No Abstract]   [Full Text] [Related]  

  • 9. Histology matters: individualizing treatment in non-small cell lung cancer.
    Neal JW
    Oncologist; 2010; 15(1):3-5. PubMed ID: 20086166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bevacizumab, when added to paclitaxel/carboplatin, prolongs survival in previously untreated patients with advanced non-small-cell lung cancer: preliminary results from the ECOG 4599 trial.
    Tyagi P
    Clin Lung Cancer; 2005 Mar; 6(5):276-8. PubMed ID: 15845177
    [No Abstract]   [Full Text] [Related]  

  • 11. Medical treatment of non-small-cell lung cancer.
    Buter J; Giaccone G
    Ann Oncol; 2005; 16 Suppl 2():ii229-32. PubMed ID: 15958463
    [No Abstract]   [Full Text] [Related]  

  • 12. Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.
    Brady AK; McNeill JD; Judy B; Bauml J; Evans TL; Cohen RB; Langer C; Vachani A; Aggarwal C
    Oncotarget; 2015 Oct; 6(30):30287-94. PubMed ID: 26471290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3-1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancer.
    Thomas M; Sadjadian P; Kollmeier J; Lowe J; Mattson P; Trout JR; Gargano M; Patchen ML; Walsh R; Beliveau M; Marier JF; Bose N; Gorden K; Schneller F
    Invest New Drugs; 2017 Jun; 35(3):345-358. PubMed ID: 28303530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 study.
    Belani CP; Schreeder MT; Steis RG; Guidice RA; Marsland TA; Butler EH; Ramalingam SS
    Cancer; 2008 Nov; 113(9):2512-7. PubMed ID: 18816622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted therapy for the treatment of non-small cell lung cancer: focus on inhibition of epidermal growth factor receptor.
    Harichand-Herdt S; Ramalingam SS
    Semin Thorac Cardiovasc Surg; 2008; 20(3):217-23. PubMed ID: 19038731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study.
    Herbst RS; Redman MW; Kim ES; Semrad TJ; Bazhenova L; Masters G; Oettel K; Guaglianone P; Reynolds C; Karnad A; Arnold SM; Varella-Garcia M; Moon J; Mack PC; Blanke CD; Hirsch FR; Kelly K; Gandara DR
    Lancet Oncol; 2018 Jan; 19(1):101-114. PubMed ID: 29169877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New insights in drug development for the non-small cell lung cancer therapy.
    Gridelli C; Rossi A; Maione P; Ferrara C; Del Gaizo F; Guerriero C; Nicolella D; Palazzolo G; Falanga M; Colantuoni G
    Front Biosci; 2008 May; 13():5108-19. PubMed ID: 18508573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pembrolizumab Outperforms Docetaxel for NSCLC.
    Leslie M
    Cancer Discov; 2016 Mar; 6(3):223. PubMed ID: 26811324
    [No Abstract]   [Full Text] [Related]  

  • 19. Predicting response of molecular targeted therapies: a still possible challenge?
    Labianca R; Garassino M; Torri V
    Ann Oncol; 2008 May; 19(5):829-30. PubMed ID: 18296420
    [No Abstract]   [Full Text] [Related]  

  • 20. Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer.
    Ready N
    Semin Oncol; 2005 Apr; 32(2 Suppl 3):S35-41. PubMed ID: 16015534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.